Patrick Daly

DocwireNews

Haris Ali and collaborating researchers evaluated the combination of selinexor and ruxolitinib in patients with treatment-na&iuml;ve myelofibrosis. In their data, presented at the 2022 American Society of Clinical Oncology Annual Meeting, the researchers reported that the combination was well-tolerated with manageable side effects, and no dose limited toxicities were reported.At the time of the presentation, the study had enrolled 10 patients to two selinexor dosage groups, 40 mg (n = 3) and 60 mg (n = 7). Ruxolitinib was started at 20 mg in eight patients, 15 mg in one patient, and 10 mg in one patient. No unmanageable toxicities were seen in either dosage group, though one patient interrupted treatment and later discontinued due to new onset atrial fibrillation and pulmonary hypertension after five months of intervention treatment. The most common treatment-emergent adverse event was low-grade nausea in 30% of patients.All patients maintained hemoglobin levels and achieved improvements in white blood cell count. Finally, among the first five evaluable patients, four experienced a &ge;35% reduction in spleen volume at week 12.Ultimately, the authors presented their preliminary data in support of the use of combined selinexor and ruxolitinib in patients with myelofibrosis.

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Selinexor Plus Ruxolitinib Patients with Treatment-Naïve Myelofibrosis

ASCO 2022

Haris Ali and collaborating researchers evaluated the combination of selinexor and ruxolitinib in patients with treatment-naïve myelofibrosis. In their data, presented at the ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe